-
Lancet Oncol: Trastuzumab + Pertuzumab ± Paclitaxel De-escalation for HER2+/HR- Early Breast Cancer
Time of Update: 2022-05-20
breast cancerThe WSG-ADAPT-HER2+/HR- trial was an investigator-initiated, multicenter, open-label, randomized Phase 2 study recruiting 18 years of age and older, histologically confirmed, unilateral, primary invasive, Patients with hormone receptor-negative and HER2-positive, non-inflammatory early breast cancer were randomized (5:2) to receive trastuzumab (8 mg/kg for the first dose, followed by 6 mg/kg for 3 weeks) + Pertuzumab (the first dose of 840 mg/kg, followed by 420 mg/kg for 3 weeks) or trastuzumab + pertuzumab + paclitaxel (80 mg/m2 weekly) .
-
Br J Cancer: Sodium ion concentration in breast cancer predicts tumor malignancy and treatment response
Time of Update: 2022-05-20
The + 23 Na MRI imaging technique can enhance the diagnostic power of DWI with higher sensitivity, which may serve as a potential non-invasive biomarker of disease malignancy and treatment response .
-
Nat Commun: Scientists discover potential therapeutic target for pancreatic cancer
Time of Update: 2022-05-20
immunityRecently, an academic paper titled "USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer" published in Nature Communications found that USP25 acts as a basic DUB required for PDAC tumor growth and viability.
-
Eight tables to help you figure out the classification of anticancer drugs
Time of Update: 2022-05-20
Small molecule targeted drugs Currently commonly used targeted drugs include anti-EGFR, ALK, MET and other inhibitors, as well as multi-target multi-kinase inhibitors .
Currently commonly used targeted drugs include anti-EGFR, ALK, MET and other inhibitors, as well as multi-target multi-kinase inhibitors .
-
Trastuzumab Deruxtecan outperforms trastuzumab emtansine in HER2-positive breast cancer
Time of Update: 2022-05-20
For patients with disease progression after treatment, the standard second-line treatment is T-DM1, an antibody-drug conjugate that combines the HER2-targeted antitumor properties of trastuzumab and the cytotoxic properties of the microtubule inhibitor DM1 active .
-
Lancet: Segmentectomy is expected to become the standard procedure for small peripheral NSCLC!
Time of Update: 2022-05-20
1%, respectively The 5-year overall survival rates in the segmentectomy and lobectomy groups were 94.
This study is the first phase 3 trial to demonstrate an overall survival benefit of segmentectomy versus lobectomy in patients with small peripheral NSCLC .
-
Science Translational Medicine: Are foreign immune cells good for infection?
Time of Update: 2022-05-20
Orex-HA mice, a hypothalamic orexinergic neuron that selectively expresses the self-antigen hemagglutinin (HA), rapidly increased the number of CD8-positive T cells in the hypothalamic region following intravenous injection of HA-specific effector CD8-positive T cells The subsequent increase in expression of CD69 and CD103 was evident on day 8 post-injection, suggesting that CD8-positive T-RM cells reside in the hypothalamus .
-
Cancer Med: New achievements of Chinese scientists!
Time of Update: 2022-05-20
Image Credit: Unsplash/CC0 Public DomainIn this study, the researchers used exosomes produced by specialized cells called lipid-derived mesenchymal stem cells (ADSCs) to deliver RNA-based (miR-138-5p) Anticancer therapy, which effectively treats bladder cancer in mice .
-
Nature Nanotechnology: Liu Gang's team from Xiamen University developed a new nanovesicle vaccine platform that can mediate super anti-tumor immune activity
Time of Update: 2022-05-20
A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategyThis study discovered an important mechanism of co-stimulatory signaling on the remodeling of T cell function in tumor immune tolerance , and reported for the first time a biomimetic cell membrane vesicle that can directly activate both naive T cells and exhausted T cells to fight tumors.
-
Nat Commun: Scientists discover potential targets for tumor immunotherapy!
Time of Update: 2022-05-20
immune tumor immunityIn this study, to unbiasedly and systematically screen for post-transcriptional regulators of PD-L1, we constructed a new custom RBP CRISPR mini-library containing 10 single guides per gene of 1467 known RBPs (sg)RNA, as well as positive and negative control sgRNAs, were used to quantify PD-L1 expression levels using fluorescence-activated single-cell sorting (FACS), and by incorporating CRISPR screens, DENR was identified as a regulator of PD-L1 .
-
Nat Metab: Gut microbial metabolite formate may exacerbate the development of colorectal cancer
Time of Update: 2022-05-20
Further studies revealed that microbiome-derived formate could drive CRC invasion by mediating the AhR signaling pathway and increase the stem cell properties of tumor cells .
-
J Immunother Cancer: Bempegaldesleukin combined with nivolumab in first-line treatment of advanced renal cell carcinoma
Time of Update: 2022-05-20
In patients with advanced clear cell renal cell carcinoma , BEMPEG combined with nivolumab as first-line therapy showed preliminary antitumor activity and was well tolerated Treatment regimen showed preliminary antitumor activity and was well tolerated Original source:Original source:Tannir Nizar M, Cho Daniel C, Diab Adi et al.
-
Pemetrexed: Folic acid and VB12 applied 1 week in advance or at the same time?
Time of Update: 2022-05-20
Timing offolic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
Timing offolic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
-
Lancet Oncol: Long-term outcomes of pembrolizumab vs chemotherapy in metastatic colorectal cancer with high microsatellite instability/mismatch repair deficiency
Time of Update: 2022-05-20
Compared with chemotherapy, pembrolizumab prolonged progression-free survival in patients with newly diagnosed metastatic colorectal cancer with high microsatellite instability or positive mismatch repair deficiency .
33 95In conclusion, although pembrolizumab demonstrated durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two groups .
-
J Clin Oncol: Efficacy and safety of Durvalumab±Oleclumab/Monalizumab consolidation therapy in stage 3 non-small cell lung cancer
Time of Update: 2022-05-20
In conclusion, compared with Durvalumab monotherapy, the two combination regimens can relatively improve the objective response rate and prolong the progression-free survival without increasing safety issues .
Compared with Durvalumab monotherapy, both combination regimens can relatively improve objective response rate and prolong progression-free survival without increasing safety issues.
-
JTO: Professor Fang Wentao's team released the world's first postoperative recurrence prediction model for thymoma
Time of Update: 2022-05-20
This study included patients who met the following criteria: (1) Histologically confirmed thymic tumors, including thymoma, thymic carcinoma, and neuroendocrine thymoma (NETT); (2) Complete surgical resection (R0, no residual disease); (3) ) International Association for the Study of Lung Cancer/International Thymic Malignancy Interest Group (IASLC/ITMIG) stage I to IIIa disease; (4) No pretreatment before surgery .
-
Small: National Nanoscience Center builds personalized multifunctional tumor in situ vaccine based on natural nanomaterials
Time of Update: 2022-05-20
In response to the above key issues in tumor vaccine research, Zhao Xiao's research team from the National Center for Nanoscience and Technology published a paper entitled: Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ in Wiley's flagship journal Small (IF=13.
-
Data of over 150,000 cancer survivors: TyG index can predict the risk of multiple CVD!
Time of Update: 2022-05-20
When analyzing the association of TyG index with CVD subtypes, the graded positive association between TyG index and clinical outcomes was particularly evident for atherosclerotic cardiovascular disease (ASCVD) such as IHD (including AMI) and ischemic stroke , not hemorrhagic stroke or heart failure .
-
A new form of vaccine - spherical nucleic acid vaccine, the first application of the new crown, the effect is amazing, has been used for cancer treatment
Time of Update: 2022-05-20
The research team developed an experimental spherical nucleic acid (SNA) drug, which was demonstrated in a clinical trial against lethal glioblastoma to penetrate the blood-brain barrier, suppress oncogene expression levels, and trigger tumor cell death .
-
One picture to understand 13 PD-1/PD-L1 drugs approved in China
Time of Update: 2022-05-20
Small cell lung cancer : a total of 2 models (PD-L1: T drug, I drug ), all of which are imported PD-L1, but the domestic PD-1 slulimumab registration phase III has reached the end point, and it is expected to be obtained within this year.